Shares of Compass Pathways PLC Sponsored ADR (NASDAQ:CMPS – Get Free Report) have been given an average recommendation of “Moderate Buy” by the seventeen brokerages that are covering the company, Marketbeat.com reports. One analyst has rated the stock with a sell recommendation, one has issued a hold recommendation, fourteen have issued a buy recommendation and one has given a strong buy recommendation to the company. The average 1 year target price among analysts that have covered the stock in the last year is $23.14.
A number of research analysts have commented on CMPS shares. Wall Street Zen raised shares of Compass Pathways from a “sell” rating to a “hold” rating in a research report on Monday. Weiss Ratings reiterated a “sell (d-)” rating on shares of Compass Pathways in a research note on Thursday, October 15th. Jefferies Financial Group reissued a “buy” rating on shares of Compass Pathways in a research report on Monday, November 9th. Wells Fargo & Company dropped their price objective on shares of Compass Pathways from $13.00 to $10.00 and set an “equal weight” rating on the stock in a research note on Wednesday, November 4th. Finally, Morgan Stanley boosted their price target on shares of Compass Pathways from $17.00 to $18.00 and gave the stock an “overweight” rating in a research note on Thursday, August 6th.
Check Out Our Latest Stock Report on CMPS
Compass Pathways Price Performance
Shares of NASDAQ CMPS opened at $8.65 on Friday. The company has a debt-to-equity ratio of 0.35, a quick ratio of 1.50 and a current ratio of 1.50. The firm has a fifty day moving average of $11.42 and a 200 day moving average of $10.49. The firm has a market cap of $1.23 billion, a PE ratio of -2.48 and a beta of 2.43. Compass Pathways has a one year low of $4.88 and a one year high of $15.87.
Compass Pathways (NASDAQ:CMPS – Get Free Report) last issued its quarterly earnings results on Tuesday, November 3rd. The company reported ($0.31) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.39) by $0.08. As a group, research analysts predict that Compass Pathways will post -0.78 EPS for the current fiscal year.
Institutional Trading of Compass Pathways
Several large investors have recently modified their holdings of the business. Candriam S.C.A. increased its stake in shares of Compass Pathways by 18.6% in the third quarter. Candriam S.C.A. now owns 1,510,695 shares of the company’s stock worth $18,862,000 after buying an additional 236,417 shares during the last quarter. Creek Drive Management Group LLC increased its position in shares of Compass Pathways by 91.9% in the 3rd quarter. Creek Drive Management Group LLC now owns 1,328,000 shares of the company’s stock worth $16,520,000 after purchasing an additional 636,000 shares during the last quarter. Eagle Health Investments LP increased its position in shares of Compass Pathways by 35.6% in the 1st quarter. Eagle Health Investments LP now owns 2,060,427 shares of the company’s stock worth $11,394,000 after purchasing an additional 541,039 shares during the last quarter. CenterBook Partners LP lifted its holdings in Compass Pathways by 454.1% during the 3rd quarter. CenterBook Partners LP now owns 695,943 shares of the company’s stock worth $8,658,000 after buying an additional 570,349 shares during the last quarter. Finally, Orbimed Advisors LLC acquired a new position in Compass Pathways in the first quarter worth $6,363,000. 46.19% of the stock is currently owned by institutional investors and hedge funds.
About Compass Pathways
Compass Pathways plc is a biotechnology company developing treatments for mental health conditions. Founded in 2016 by George Goldsmith and Ekaterina Malievskaia, the company is focused on advancing psychedelic-based therapies through clinical research. Its lead investigational product, COMP360, is a synthetic formulation of psilocybin being studied alongside psychological support. Compass is evaluating COMP360 primarily as a potential treatment for treatment-resistant depression and has also explored its use for other mental health conditions, including post-traumatic stress disorder.
See Also
- Five stocks we like better than Compass Pathways
- Grand Theft Auto VI Arrives: Why Take-Two Is a Waiting Game
- Greg Abel Makes His Next Moves: Inside Berkshire’s Q3 Portfolio
- Walmart Earnings Change the Narrative as Digital Growth Lifts Outlook
- Whatever Happens to Copper Next, These 3 Investments Offer Different Ways to Play It
Receive News & Ratings for Compass Pathways Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Compass Pathways and related companies with MarketBeat.com's FREE daily email newsletter.
